Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT05475171
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Lorigerlimab — DRUG
    Given by vein (IV)

Study Details

To learn if MGD019 can help to control cervical cancer in patients who have yet to receive treatment.

Key Dates

First listed
Jul 26, 2022
Start date
Dec 13, 2022
Status verified
Sep 2026
Primary completion
Jun 30, 2028
Completion
Jun 30, 2028

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Lorigerlimab
    Participants will receive Lorigerlimab by vein over about 30 minutes on Day 1 of each cycle

Primary Outcome Measure

To establish overall survival (OS) [ Time Frame: through the study completion an average of 1 year. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
M D Anderson Cancer CenterHoustonTexas77030
Amir Jazaeri, MD
[email protected]
713-745-1613
Amir Jazaeri, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

Nationwide
Cervical cancer trialsOncology trialsGynecologic oncology trialsWomen's health trials
By condition
Cervical cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
M D Anderson Cancer Center· Houston, TX

Related Studies